Publications by authors named "Fumi Inaba"

Claim this Profile
A
Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Masaki Kiga, Fumie Tanzawa, Shiho Iwasaki, Fumi Inaba, Kosaku Fujiwara

Anticancer Drugs· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic and pharmacokinetic evaluation of CS-526 in cynomolgus monkeys.
Keiichi Ito, Kazuya Kinoshita, Naotoshi Yamamura, Atsuyuki Tomizawa, Fumi Inaba

Biol Pharm Bull· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats.
Keiichi Ito, Kazuya Kinoshita, Atsuyuki Tomizawa, Yuka Morikawa-Inomata, Fumi Inaba

J Pharmacol Exp Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Keiichi Ito, Kazuya Kinoshita, Atsuyuki Tomizawa, Fumi Inaba, Yuka Morikawa-Inomata

J Pharmacol Exp Ther· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis